Body fatness and breast cancer risk in relation to phosphorylated mTOR expression in a sample of predominately Black women

Table 5 Odds ratios of breast cancer risk in relation to p-mTOR expression associated with body composition measurements by tumor ER status

Body composition measurement		ER+ tumors			ER– tumors
	p-mTOR overexpressed cases vs controls	p-mTOR negative/low cases vs controls	P-heterogeneity	p-mTOR overexpressed cases vs controls	p-mTOR negative/low cases vs controls	P-heterogeneity
	OR (95% CI)	OR (95% CI)		OR (95% CI)	OR (95% CI)
Percent body fat
No. of cases/no. of controls	156/1884	295/1884		23/1884	198/1884
Q1	1.00 [reference]	1.00 [reference]		1.00 [reference]	1.00 [reference]
Q2	1.29 (0.73–2.28)	1.10 (0.76–1.60)		1.08 (0.28–4.20)	1.53 (0.99–2.36)
Q3	1.61 (0.93–2.78)	1.06 (0.71–1.50)		1.20 (0.31–4.58)	0.84 (0.52–1.36)
Q4	1.31 (0.74–2.32)	0.67 (0.44–1.01)	0.037	1.34 (0.36–4.95)	0.73 (0.45–1.19)	0.003
P-trend	0.31	0.06		0.64	0.040
Fat mass index
No. of cases/no. of controls	155/1859	294/1859		23/1859	198/1859
Q1	1.00 [reference]	1.00 [Reference]		1.00 [Reference]	1.00 [reference]
Q2	1.26 (0.71–2.23)	1.24 (0.85–1.80)		1.06 (0.27–4.41)	1.59 (1.02–2.47)
Q3	1.36 (0.77–2.38)	1.19 (0.81–1.74)		1.23 (0.33–4.61)	0.89 (0.55–1.45)
Q4	1.48 (0.84–2.60)	0.72 (0.47–1.10)	0.011	1.09 (0.29–4.20)	0.79 (0.48–1.30)	0.004
P-trend	0.19	0.040		0.90	0.031

Abbreviations: ER estrogen receptor, OR odds ratio, Q quartile
Models adjusted for age, race, family history of breast cancer, menopausal status, age of menarche, parity, history of breastfeeding, oral contraceptive use, history of diabetes

ISSN: 1465-542X